INS and type 2 diabetes mellitus: In particular, recent work by Mone P. et al. demonstrated that the addition of empagliflozin to the therapy in a cohort of patients with HFpEF and T2DM resulted in a significant and greater increase in MoCA score compared with insulin and metformin after 1 month of therapy [15].